UXI Stock Overview

A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. More details

UXI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Earnings are forecast to grow 76.29% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue ($74K)

Negative shareholders equity

Does not have a meaningful market cap (€2M)

My Notes

Capture your thoughts, links and company narrative

Cyclacel Pharmaceuticals, Inc. Competitors

co.don

XTRA:CNW

€6.5m

Sangui Biotech International

HMSE:SBH

€419.8k

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

2invest

XTRA:2INV

€67.3m

Price History & Performance

Summary of share price highs, lows and changes for Cyclacel Pharmaceuticals
Historical stock prices
Current Share Price	US$0.55
52 Week High	US$3.06
52 Week Low	US$0.55
Beta	0.35
1 Month Change	0%
3 Month Change	-35.67%
1 Year Change	-76.55%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-79.41%

Recent updates

Shareholder Returns

	UXI	DE Biotechs	DE Market
7D	0%	-2.6%	-2.0%
1Y	-76.5%	-13.2%	6.8%

Return vs Industry: UXI underperformed the German Biotechs industry which returned -14.7% over the past year.

Return vs Market: UXI underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is UXI's price volatile compared to industry and market?
UXI volatility
UXI Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.9%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.4%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine UXI's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1996	n/a	Spiro Rombotis	www.cyclacel.com

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company’s lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias.

Cyclacel Pharmaceuticals, Inc. Fundamentals Summary

How do Cyclacel Pharmaceuticals's earnings and revenue compare to its market cap?
UXI fundamental statistics
Market cap	€1.92m
Earnings (TTM)	-€12.97m
Revenue (TTM)	€71.17k

27.0x

P/S Ratio

-0.1x

P/E Ratio

Is UXI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UXI income statement (TTM)
Revenue	US$74.00k
Cost of Revenue	US$0
Gross Profit	US$74.00k
Other Expenses	US$13.56m
Earnings	-US$13.48m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.14
Gross Margin	100.00%
Net Profit Margin	-18,217.57%
Debt/Equity Ratio	0%

How did UXI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 12:35
End of Day Share Price	2024/11/04 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cyclacel Pharmaceuticals, Inc. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Andrew Fein	H.C. Wainwright & Co.
Kimberly Lee	Janney Montgomery Scott LLC
Michael King	JMP Securities